De-Escalation of Disease-Modifying Therapy in Multiple Sclerosis-A Danish Nationwide Cohort Study.

ABSTRACT:

Background and objective

High-efficacy (HE) disease-modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in aging patients. We aimed to describe disease activity and treatment trajectories in patients with MS who de-escalated from an HE DMT to an moderate-efficacy (ME) DMT.

Methods

We performed a cohort study based on data from the Danish Multiple Sclerosis Registry (DMSR) including patients with relapsing-remitting MS (RRMS), who switched from an HE DMT to an ME DMT as defined by Danish authorities. We included patients from October 2007 to July 2023. Median follow-up time was 0.8 years (IQR 0.3-2.5).

Results

In total 333 patients (76.0% females,

SUBMITTER: Elberling F 

PROVIDER: S-EPMC11788534 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature